The discovery that many melanomas harbor BRAF mutations29 led to the development of vemurafenib and dabrafenib, selective inhibitors of the BRAF V600-mutated kinase, and trametinib and cobimetinib, inhibitors of the downstream MEK kinase. This evidence concerns the gene BRAF and melanoma.